Tag Archives: Prospectus Department

Caesarstone Announces Pricing of Ordinary Shares Offering by Selling Shareholders

By Business Wirevia The Motley Fool

Filed under:

Caesarstone Announces Pricing of Ordinary Shares Offering by Selling Shareholders

MP MENASHE, Israel–(BUSINESS WIRE)– Caesarstone Sdot-Yam Ltd. (NAS: CSTE) , a leading manufacturer of high quality engineered quartz surfaces, today announced the pricing at $23.25 per share of an underwritten public offering of 7,775,000 ordinary shares offered by its shareholders, Kibbutz Sdot-Yam and Tene Investment Fund. The selling shareholders have also granted the underwriters a 30-day option to purchase up to 1,166,250 additional ordinary shares. Caesarstone will not receive any proceeds from the offering. The offering is expected to close on April 17, 2013.

J.P. Morgan Securities LLC, Barclays Capital Inc. and Credit Suisse Securities (USA) LLC acted as joint bookrunning managers for the offering, and Stifel, Nicolaus & Company, Incorporated and Robert W. Baird & Co. Incorporated acted as co-managers for the offering.

A shelf registration statement (including a prospectus) relating to these securities was filed by Caesarstone and declared effective on April 5, 2013 by the Securities and Exchange Commission (SEC). A copy of the prospectus supplement and base prospectus relating to the offering may be obtained by contacting: J.P. Morgan Securities LLC, via telephone at (866) 803-9204 or by mail at Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; Barclays Capital Inc., via telephone at (888) 603-5847, by mail at c/o Barclays Capital Inc. at Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or barclaysprospectus@broadridge.com; or Credit Suisse Securities (USA) LLC, via telephone at (800) 221-1037, by mail at Prospectus Department, One Madison Avenue, New York, NY, 10010 or newyork.prospectus@credit-suisse.com. Before you invest, you should read these documents and other documents filed by Caesarstone with the SEC for more complete information. You may obtain these documents free of charge by visiting the SEC‘s website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Caesarstone

Caesarstone manufactures high quality engineered quartz surfaces, which are used in both residential and commercial buildings as countertops and other interior surfaces. The wide variety of colors, styles, designs and textures of Caesarstone® products, along

From: http://www.dailyfinance.com/2013/04/11/caesarstone-announces-pricing-of-ordinary-shares-o/

Cancer Genetics, Inc. Announces Closing of Initial Public Offering of 690,000 Shares of Common Stock

By Business Wirevia The Motley Fool

Filed under:

Cancer Genetics, Inc. Announces Closing of Initial Public Offering of 690,000 Shares of Common Stock

RUTHERFORD, N.J.–(BUSINESS WIRE)– Cancer Genetics, Inc. (OTCQB: CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced it has closed its initial public offering of 690,000 shares of common stock (including 90,000 shares that were offered and sold by Cancer Genetics pursuant to the exercise in-full of the underwriters’ over-allotment option) at a price to the public of $10.00 per share. Total gross proceeds from the offering were $6,900,000, before deducting underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.

Aegis Capital Corp. acted as sole book-running manager for the offering.

Feltl and Company, Inc. acted as co-manager for the offering.

This offering was made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 4, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cancer Genetics:

Cancer Genetics, Inc. is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer. The proprietary tests being developed by Cancer Genetics target cancers that are difficult to prognose and predict treatment outcomes using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers. Cancer Genetics recently has begun to provide its proprietary tests and services along with a comprehensive range of non-proprietary oncology-focused tests and laboratory services that it has provided historically to oncologists and pathologists at hospitals, cancer centers and physician offices. Cancer Genetics is currently offering its tests and laboratory services in its 17,936 square foot laboratory located in Rutherford, New Jersey, which has been accredited under the Clinical Laboratory Improvement Amendments of 1988 to perform high complexity testing.

Caesarstone Announces Offering of Ordinary Shares by Selling Shareholders

By Business Wirevia The Motley Fool

Filed under:

Caesarstone Announces Offering of Ordinary Shares by Selling Shareholders

MP MENASHE, Israel–(BUSINESS WIRE)– Caesarstone Sdot-Yam Ltd. (NAS: CSTE) , a leading manufacturer of high quality engineered quartz surfaces, today announced that its shareholders, Kibbutz Sdot-Yam and Tene Investment Fund, are offering for sale 7,250,000 ordinary shares of the company in an underwritten public offering. Caesarstone will not receive any proceeds from the offering.

J.P. Morgan Securities LLC, Barclays Capital Inc. and Credit Suisse Securities (USA) LLC are the joint bookrunning managers for the proposed offering, and Stifel, Nicolaus & Company, Incorporated and Robert W. Baird & Co. Incorporated are the co-managers for the proposed offering.

A shelf registration statement (including a prospectus) relating to these securities was filed by Caesarstone and declared effective on April 5, 2013 by the Securities and Exchange Commission (SEC). A copy of the prospectus supplement and base prospectus relating to the offering may be obtained by contacting: J.P. Morgan Securities LLC, via telephone at (866) 803-9204 or by mail at Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; Barclays Capital Inc., via telephone at (888) 603-5847, by mail at c/o Barclays Capital Inc. at Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or barclaysprospectus@broadridge.com; or Credit Suisse Securities (USA) LLC, via telephone at (800) 221-1037, by mail at Prospectus Department, One Madison Avenue, New York, NY, 10010 or newyork.prospectus@credit-suisse.com. Before you invest, you should read these documents and other documents filed by Caesarstone with the SEC for more complete information. You may obtain these documents free of charge by visiting the SEC‘s website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Caesarstone

Caesarstone manufactures high quality engineered quartz surfaces, which are used in both residential and commercial buildings as countertops and other interior surfaces. The wide variety of colors, styles, designs and textures of Caesarstone® products, along with Caesarstone’s inherent characteristics such as hardness, non-porous, scratch and stain resistance and durability, provide consumers with a product competitive to granite, manufactured solid surfaces and laminate, as well as to other engineered quartz surfaces. Caesarstone’s four collections …read more

Source: FULL ARTICLE at DailyFinance

Cancer Genetics, Inc. Announces Full Exercise of Over-Allotment Option

By Business Wirevia The Motley Fool

Filed under:

Cancer Genetics, Inc. Announces Full Exercise of Over-Allotment Option

RUTHERFORD, N.J.–(BUSINESS WIRE)– Cancer Genetics, Inc. (OTCQB: CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 90,000 shares of its common stock, at a price to the public of $10.00 per share, in connection with its previously announced underwritten initial public offering of 600,000 shares of common stock, bringing expected total gross proceeds from the offering to $6,900,000, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.

Aegis Capital Corp. is acting as sole book-running manager for the offering.

Feltl and Company, Inc. is acting as co-manager for the offering.

This offering is being made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 4, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cancer Genetics:

Cancer Genetics, Inc. is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer. The proprietary tests being developed by Cancer Genetics target cancers that are difficult to prognose and predict treatment outcomes by using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers. Cancer Genetics recently has begun to provide its proprietary tests and services along with a comprehensive range of non-proprietary oncology-focused tests and laboratory services that it has provided historically to oncologists and pathologists at hospitals, cancer centers and physician offices. Cancer Genetics is currently offering its tests and laboratory services in its 17,936 square foot laboratory located in Rutherford, New Jersey, which has been accredited under the Clinical Laboratory Improvement Amendments of 1988 to perform high complexity testing.

<div class="image …read more

Source: FULL ARTICLE at DailyFinance

Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock

By Business Wirevia The Motley Fool

Filed under:

Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock

RUTHERFORD, N.J.–(BUSINESS WIRE)– Cancer Genetics, Inc., a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the pricing of its initial public offering of 600,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Cancer Genetics from the initial public offering are expected to be $6,000,000 (assuming no exercise of the over-allotment option), before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics. Cancer Genetics has granted the representative of the underwriters a 45-day option to purchase up to 90,000 additional shares of common stock from Cancer Genetics to cover over-allotments, if any. Shares of Cancer Genetics‘ common stock are expected to be quoted on the OTCQB Marketplace, operated by OTC Markets Group, under the symbol “CGIX” beginning on April 5, 2013. Investors will be able to find Real Time Level II quotes for “CGIX” on www.otcmarkets.com.

The offering is expected to close on April 10, 2013, subject to customary closing conditions.

Aegis Capital Corp. is acting as sole book-running manager for the offering.

Feltl and Company, Inc. is acting as co-manager for the offering.

This offering is being made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 4, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cancer Genetics:

Cancer Genetics, Inc. is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer. The proprietary tests being developed by Cancer Genetics target cancers that are difficult to prognose and predict treatment outcomes by using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers. Cancer Genetics recently …read more

Source: FULL ARTICLE at DailyFinance

Ares Capital Corporation Announces Public Offering

By Business Wirevia The Motley Fool

Filed under:

Ares Capital Corporation Announces Public Offering

NEW YORK–(BUSINESS WIRE)– Ares Capital Corporation (NAS: ARCC) announced that it plans to make a public offering of 16,650,000 shares of its common stock. Ares Capital also plans to grant the underwriters an option to purchase up to an additional 2,497,500 shares of common stock. The offering of the shares will be made under Ares Capital‘s shelf registration statement (as amended), which was filed with, and declared effective by, the Securities and Exchange Commission.

Ares Capital expects to use the net proceeds of this offering to repay certain outstanding indebtedness under its debt facilities and, to the extent not used for such purpose, for general corporate purposes, which may include investing in portfolio companies in accordance with its investment objective.

Investors are advised to carefully consider the investment objective, risks, charges and expenses of Ares Capital before investing. The preliminary prospectus supplement dated April 2, 2013 and the accompanying prospectus dated August 16, 2012, which have been filed with the Securities and Exchange Commission, contain this and other information about Ares Capital and should be read carefully before investing.

BofA Merrill Lynch, J.P. Morgan, Morgan Stanley and UBS Investment Bank are acting as joint book-running managers for this offering.

The information in the preliminary prospectus supplement, the accompanying prospectus and this press release is not complete and may be changed. The preliminary prospectus supplement, the accompanying prospectus and this press release are not offers to sell any securities of Ares Capital and are not soliciting an offer to buy such securities in any state where such offer and sale is not permitted.

The offering may be made only by means of a preliminary prospectus supplement and an accompanying prospectus, copies of which may be obtained from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or e-mail dg.prospectus_requests@baml.com ; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, 866-803-9204; Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY, 10014, Attn: Prospectus Department, tel.: (866) 718-1649 or e-mail prospectus@morganstanley.com ; or UBS Investment Bank, Attn: Prospectus Department, 299 Park Avenue, New York, NY 10171, tel.: (888) 827-7275.

ABOUT ARES CAPITAL CORPORATION

…read more
Source: FULL ARTICLE at DailyFinance

Weingarten Realty Investors Announces Pricing of $300 Million Public Offering of Senior Unsecured No

By Business Wirevia The Motley Fool

Filed under:

Weingarten Realty Investors Announces Pricing of $300 Million Public Offering of Senior Unsecured Notes

HOUSTON–(BUSINESS WIRE)– Weingarten Realty Investors (NYS: WRI) announced today the pricing of $300 million of 3.50% Notes due 2023 in an underwritten public offering. The notes were offered at 99.528% of the principal amount with a yield to maturity of 3.556%. The offering is scheduled to close on March 22, 2013, subject to customary closing conditions.

Weingarten intends to use the net proceeds of the offering to repay amounts outstanding under its unsecured revolving credit facility and general business purposes.

Merrill Lynch, Pierce, Fenner & Smith Incorporated, U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC served as joint book-running managers. Regions Securities LLC, PNC Capital Markets LLC, Scotia Capital (USA) Inc., The Williams Capital Group, L.P. and SMBC Nikko Capital Markets Limited served as co-managers for the offering.

Copies of the prospectus and related prospectus supplement, when available, may be obtained from: Merrill Lynch, Pierce, Fenner & Smith Incorporated, 222 Broadway, 11th Floor, New York, New York 10038, attention: Prospectus Department, telephone: (800) 294-1322, email: dg.prospectus_requests@baml.com, U.S. Bancorp Investments, Inc. at (877) 558-2607 or Wells Fargo Securities, LLC, 1525 West W.T. Harris Blvd., NC0675, Charlotte, NC 28262, Attn: Capital Markets Client Support, toll-free: (800) 326-5897 or emailing: cmclientsupport@wellsfargo.com.

An effective registration statement is on file with the Securities and Exchange Commission (“SEC“), and a copy of the prospectus supplement, together with the prospectus, also will be available on the SEC‘s website at www.sec.gov. This news release does not constitute an offer to sell or a solicitation of any offer to buy such securities nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Weingarten Realty Investors

Weingarten Realty Investors (NYS: WRI) is a commercial real estate owner, manager and developer. At December 31, 2012, the Company owned or operated under long-term leases, either directly or through its interest in real estate joint ventures or partnerships, a total of 292 developed income-producing properties and two properties under various stages of construction and development. The total number of properties includes 288 neighborhood and community shopping centers and six other operating properties …read more
Source: FULL ARTICLE at DailyFinance

Artisan Partners Asset Management Inc. Prices Initial Public Offering

By Business Wirevia The Motley Fool

Filed under:

Artisan Partners Asset Management Inc. Prices Initial Public Offering

MILWAUKEE–(BUSINESS WIRE)– Artisan Partners Asset Management Inc. (the “Company”) announced today the pricing of its initial public offering of 11,054,156 shares of Class A common stock at a price to the public of $30.00 per share. The Company has granted the underwriters an option to purchase up to 1,658,123 additional shares at the initial public offering price less underwriting discounts and commissions. The Company’s Class A common stock is expected to begin trading on the New York Stock Exchange under the symbol “APAM” on March 7, 2013. The offering is expected to close on March 12, 2013, subject to customary closing conditions.

Artisan Partners Limited Partnership (“Artisan Partners“), the Company’s primary operating entity upon completion of the initial public offering, is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. Artisan Partners has five autonomous investment teams that oversee twelve distinct U.S., non-U.S. and global investment strategies. Each strategy is offered through multiple investment vehicles, including Artisan Partners Funds, Inc., to accommodate a broad range of client mandates. As of February 15, 2013, Artisan Partners had approximately $79.5 billion in assets under management.

A registration statement relating to the Company’s Class A common stock has been filed with and declared effective by the Securities and Exchange Commission. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering, when available, may be obtained from Citigroup Global Markets, Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 800.831.9146, email: batprospectusdept@citi.com; or Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY 10282, telephone: 866.471.2526, facsimile: 212.902.9316, email: prospectus-ny@ny.email.gs.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Artisan Partners Asset Management Inc.
Investor Relations Inquiries:
Makela Taphorn
866.632.1770
ir@artisanpartners.com
or
Press Inquiries:
Bob Batchelor
866.642.1770
pr@artisanpartners.com

KEYWORDS:   United States  North America  Wisconsin

INDUSTRY KEYWORDS:

The article Artisan Partners Asset Management Inc. Prices Initial Public Offering originally appeared on Fool.com.

…read more
Source: FULL ARTICLE at DailyFinance